Fosun Pharma Subsidiary to Invest RMB 414 Million in Series B Financing and Equity Transfer of Liver Disease Innovator Xingyao Kunze

Gelonghui, May 26 |Fosun Pharmaceutical(600196.SH) announced that its controlling subsidiary, Fosun Pharmaceutical Industry, plans to invest a total of RMB 414 million to participate in the Series B financing round of Hepa Thera and acquire certain equity interests held by its associated companies, Suzhou Fund and Tianjin Fund. Specifically, it intends to contribute RMB 218 million to subscribe for RMB 2.9368 million in newly registered capital of Hepa Thera, and invest RMB 197 million to acquire a combined RMB 3.0865 million in existing registered capital held by the Suzhou Fund and Tianjin Fund. Upon completion of the transaction, Fosun Pharmaceutical Industry will hold a 20.87% equity stake in Hepa Thera. The target company is primarily engaged in the research and development of innovative drugs for liver diseases. This investment constitutes a related-party transaction and aims to enrich the Company's pipeline layout in the field of liver disease treatment.